News & Events


Welcome Dr. Frank Santoro As Chief Medical Officer At Synteract

Welcome Dr. Frank Santoro As Chief Medical Officer At Synteract
16 August 2017

With clinical trials continuing to grow in complexity, effective communication across drug development projects and the role of medical affairs as it relates to this is more important than ever. As a full-service, international CRO with three decades of successfully supporting clinical development, we are always looking for ways to innovate and for leaders that will help drive continued improvement. One of our most recent senior hires, Dr. Frank Santoro, who joins us as Chief Medical Officer, is a case in point.

With more than 30 years’ experience, Dr. Santoro has worked at both CROs and pharmaceutical companies, in virtually every therapeutic area, including numerous oncology studies. He has directed project team activities for multi-therapeutic Phase I-IV research programs and has served as project physician for numerous domestic and international studies. Most recently he was Chief Medical Officer for Novella Clinical and, before that, Vice President of Clinical Development and Medical Affairs for Protherics, a UK-based biopharmaceutical company working in oncology and critical care.

Dr. Santoro will help to further our robust medical and scientific capabilities in oncology, immunotherapy, CNS, and infectious disease, advancing the expertise we offer clients across the life cycle of their projects. He will also drive growth in personalized medicine, gene and cell therapies and other therapeutic areas as they evolve in the next decade.

Please joins us in welcoming him to Synteract!

For more on Synteract’s end-to-end medical guidance and therapeutic expertise please visit or contact Dr. Santoro and his team directly to see how they can help you.


Contact Synteract

Tell us how to stay in touch with you: